Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bimatoprost (Lumigan) Clear all
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

NCT00693420
View directory record Official record
Conditions
Eyelashes
Interventions
Bimatoprost 0.03% sterile solution, vehicle sterile solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

NCT00440011
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03% eye drops, travoprost 0.004% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

NCT01064882
View directory record Official record
Conditions
Eyelash Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
30 Years to 55 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Bimatoprost in the Treatment of Eyelash Hypotrichosis

NCT01698554
View directory record Official record
Conditions
Idiopathic Eyelash Hypotrichosis
Interventions
bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

NCT01448525
View directory record Official record
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

NCT01765764
View directory record Official record
Conditions
Eyebrow Hypotrichosis
Interventions
bimatoprost solution, Vehicle to bimatoprost solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

The Effects of the Water Drinking Test on Intraocular Pressure

NCT01507584
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01253902
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

NCT00539526
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 8, 2026, 11:56 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

NCT00999557
View directory record Official record
Conditions
Alopecia, Breast Cancer
Interventions
bimatoprost ophthalmic solution, placebo
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

NCT00332072
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01177098
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT00538304
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost eye drops, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 8, 2026, 11:56 AM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 8, 2026, 11:56 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

NCT01426113
View directory record Official record
Conditions
Glaucoma
Interventions
bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

NCT00355446
View directory record Official record
Conditions
Cataract
Interventions
Bimatoprost 0.03%
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 8, 2026, 11:56 AM EDT
Completed No phase listed Observational Results available

Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

NCT02138461
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
MDbackline, LLC
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

NCT04738149
View directory record Official record
Conditions
Vitiligo
Interventions
Bimatoprost, Excimer laser, Microneedling with a dermaroller
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of 0.01% Bimatoprost

NCT01271686
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma, Ocular Hypertension
Interventions
0.01% bimatoprost
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 8, 2026, 11:56 AM EDT
Recruiting Early Phase 1 Interventional

Bimatoprost as a Treatment for Graves' Orbitopathy

NCT03708627
View directory record Official record
Conditions
Graves Ophthalmopathy
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 8, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 8, 2026, 11:56 AM EDT